Cytomegalovirus Retinitis in a Patient Treated with Anti--Tumor Necrosis Factor Alpha Antibody Therapy for Rheumatoid Arthritis | Zendy

Georg Haerter | Zendy; Burkhard Manfras | Zendy; Yvonne de JongHesse | Zendy; H. Wilts | Zendy; Thomas Mertens | Zendy; Peter Kern | Zendy; MariePaule Schmitt | Zendy

Open Access

Cytomegalovirus Retinitis in a Patient Treated with Anti--Tumor Necrosis Factor Alpha Antibody Therapy for Rheumatoid Arthritis

Author(s) -

Georg Haerter,

Burkhard Manfras,

Yvonne de JongHesse,

H. Wilts,

Thomas Mertens,

Peter Kern,

MariePaule Schmitt

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/425123

Subject(s) - medicine , cytomegalovirus retinitis , valganciclovir , rheumatoid arthritis , retinitis , ganciclovir , immunology , arthritis , infliximab , antibody , gastroenterology , tumor necrosis factor alpha , human cytomegalovirus , virus

Anti-tumor necrosis factor alpha (anti-TNF- alpha ) antibodies have been used for the treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and psoriasis arthritis. Such antibody therapies result in a severe interference with the patient's immune system. Increased rates of upper respiratory tract infection, reactivation of latent tuberculosis, and other systemic infectious diseases have been reported among patients receiving anti-TNF- alpha antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research